We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > HFB30132A

News List

HiFiBiO, Pharmsynthez and IBCh sign Covid-19 antibody development deal pharmaceutical-technology
November 25, 2020
HiFiBiO Therapeutics has entered into a partnership with Pharmsynthez and Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry RAS (IBCh) to develop and commercialise its SARS-CoV-2 neutralising antibody, HFB30132A, for Covid-19 treatment.
HiFiBiO completes first cohort of phase 1 study of SARS-CoV-2 neutralising antibody pharmaceutical-business-review
October 29, 2020
HiFiBiO Therapeutics announced the successful completion of the first cohort of the Phase I study (NCT04590430) of HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment and prevention of COVID-19.
HiFiBiO, ABL Bio to co-develop HFB30132A antibody for Covid-19 pharmaceutical-business-review
September 17, 2020
HiFiBiO Therapeutics has entered into a partnership with South Korea-based ABL Bio to co-develop its SARS-CoV-2 neutralising antibody HFB30132A for the treatment of Covid-19.
HiFiBiO submits IND application for SARS-CoV-2 neutralising antibody to treat Covid-19 patients pharmaceutical-business-review
August 31, 2020
HiFiBiO Therapeutics announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for a novel SARS-CoV-2 neutralizing antibody for the treatment of Covid-19 patients.